[Tetracosactide (Synacthen Depot) in patients with multiple sclerosis]

Area of Science:

• Neurology
• Immunology
• Pharmacology

Background:

• Multiple Sclerosis (MS) is a chronic neurological disease.
• Tetracosactrin (Synacthen Depot) is used to treat MS exacerbations.
• Patient management requires understanding potential adverse drug reactions.

Observation:

• A study involved 292 patients with clinically definite multiple sclerosis.
• 91 patients received Tetracosactrin during initial or exacerbation attacks.
• Two female patients developed anaphylaxis during Tetracosactrin treatment.

Findings:

• Anaphylaxis occurred after the sixth and twenty-second injections in the affected patients.
• Cutaneous tests for zinc oxide were negative.
• Elevated immunoglobulin E (IgE) levels and positive RAST tests for Tetracosactrin were observed.

Implications:

• These findings suggest an immediate allergic reaction to Tetracosactrin, mediated by reagins.
• Careful patient selection and monitoring are crucial when administering Tetracosactrin.
• Further research into the immunological mechanisms of Tetracosactrin hypersensitivity is warranted.